Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smart Stop: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab With/Without Chemotherapy in Newly Diagnosed DLBCL
NCT04978584Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, lenalidomide, acalabrutinib tablet (Variant 1) and tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate and Complete Response Rate. Started Mar 2022; status: active, not recruiting.
02
Drugs
rituximablenalidomideacalabrutinib tablet (Variant 1)tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04978584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978584.